Insider · CIK 0001521548
Michael Halstead
presidentofficerceo
Files at ITCI (Intra-Cellular Therapies, Inc.), HELP (Helus Pharma Inc.). First filing Nov 14, 2024, latest Sep 21, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 1
$1.3M bought, $3.7M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
HELP: Helus Pharma Inc.
HELPOct 9, 2026 · close 11.80
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 75Notable | Helus Pharma Inc. | $1.3M 100,000 shares | +146% | +253% from low-3% from high | |
| 30Weak | Intra-Cellular Therapies, Inc. | $3.7M 41,583 shares | -182% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | HELP Helus Pharma Inc. | POpen-market purchase Common Shares | +100,000 | $13.47 | $1.3M | 168,568 | 21 d ago |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Common Stock | -21,307 | $132.00 | $2.8M | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -40,472 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -17,916 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -13,133 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -24,478 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -45,454 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Performance Stock Unitsderivative | +13,134 | $0.00 | $0 | 13,134 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Performance Stock Unitsderivative | -13,134 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Performance Stock Unitsderivative | +12,240 | $0.00 | $0 | 12,240 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Performance Stock Unitsderivative | -12,240 | - | - | 0 | Apr 2, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +13,133 | - | - | 24,437 | Mar 10, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -6,718 | $131.19 | $881k | 17,719 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +7,345 | - | - | 25,064 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -3,757 | $131.24 | $493k | 21,307 | Mar 10, 2025 |
| Mar 6, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -13,133 | $0.00 | $0 | 13,133 | Mar 10, 2025 |
| Mar 10, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -7,345 | $0.00 | $0 | 0 | Mar 10, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock | +12,239 | - | - | 17,565 | Mar 4, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -6,261 | $128.20 | $803k | 11,304 | Mar 4, 2025 |
| Mar 1, 2025 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Restricted Stock Unitsderivative | -12,239 | $0.00 | $0 | 24,478 | Mar 4, 2025 |
| Jan 31, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Common Stock | +11,017 | $0.00 | $0 | 11,017 | Feb 4, 2025 |
| Jan 31, 2025 | ITCI Intra-Cellular Therapies, Inc. | FTax withholding Common Stock | -5,691 | $127.00 | $723k | 5,326 | Feb 4, 2025 |
| Feb 3, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Restricted Stock Unitsderivative | +45,454 | $0.00 | $0 | 45,454 | Feb 4, 2025 |
| Nov 12, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +22,869 | $23.94 | $547k | 22,869 | Nov 14, 2024 |
| Nov 12, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -15,105 | $88.72 | $1.3M | 7,764 | Nov 14, 2024 |
| Nov 12, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -6,116 | $89.63 | $548k | 1,648 | Nov 14, 2024 |
| Nov 12, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -1,648 | $90.89 | $150k | 0 | Nov 14, 2024 |
| Nov 13, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Common Stock10b5-1 | +18,714 | $36.89 | $690k | 18,714 | Nov 14, 2024 |
| Nov 13, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -13,371 | $88.17 | $1.2M | 5,343 | Nov 14, 2024 |
| Nov 13, 2024 | ITCI Intra-Cellular Therapies, Inc. | SOpen-market sale Common Stock10b5-1 | -5,343 | $88.92 | $475k | 0 | Nov 14, 2024 |
| Nov 12, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -22,869 | $0.00 | $0 | 0 | Nov 14, 2024 |
| Nov 13, 2024 | ITCI Intra-Cellular Therapies, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -18,714 | $0.00 | $0 | 0 | Nov 14, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.